Aubagio
What Aubagio is used for
AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Aubagio
- Active substance
- teriflunomide
- Disease area
- Multiple Sclerosis
- Medicine group
- Selective immunosuppressants
- ATC code
- L04AK02
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Authorised in the EU since
- 2013
Official information
In India
- Teriflunomide: 7 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Aubagio used for?
AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).
What is the active substance in Aubagio?
Aubagio contains teriflunomide.
Who makes Aubagio?
The EU marketing authorisation holder is Sanofi Winthrop Industrie.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU